Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
暂无分享,去创建一个
M. Kersten | G. Salles | C. Klein | R. Bouabdallah | P. Zinzani | P. Hagner | V. Ribrag | J. Doorduijn | Silvia Mosulén | M. Pourdehnad | U. Vitolo | J. Michot | K. Hege | A. Chiappella | Z. Nikolova | F. Bijou | R. Sarmiento | Cristina Méndez | S. Uttamsingh | Tianlei Chen | C. Méndez
[1] G. Salles,et al. Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier. , 2020, Blood.
[2] L. Fayad,et al. A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma , 2019, Blood.
[3] R. Houot,et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. , 2019, The Lancet. Haematology.
[4] J. Gribben,et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] I. Flinn,et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Houot,et al. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study , 2018, Leukemia.
[7] K. Papadopoulos,et al. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies , 2018, Clinical Cancer Research.
[8] G. Salles,et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma , 2018, The New England journal of medicine.
[9] G. Lenz,et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W. Klapper,et al. Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma , 2017, The New England journal of medicine.
[11] A. Bhatt. International Council for Harmonisation E6(R2) addendum: Challenges of implementation , 2017, Perspectives in clinical research.
[12] J. Gribben,et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. , 2016, The Lancet. Oncology.
[13] J. Cerhan,et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Trotter,et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. , 2015, Blood.
[15] S. Barrington,et al. Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19–20 September 2014 , 2015, Leukemia & lymphoma.
[16] Bruce D Cheson,et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Tuscano,et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma , 2014, British journal of haematology.
[18] S. Barrington,et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012 , 2014, Leukemia & lymphoma.
[19] R. Chopra,et al. A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma , 2013 .
[20] M. Chao. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies , 2013, Cancer management and research.
[21] H. Tilly,et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[22] R. Chopra,et al. Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression , 2012, British journal of haematology.
[23] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Jeffrey S Barrett,et al. Shortening the timeline of pediatric phase I trials: the rolling six design. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Randy D Gascoyne,et al. Non-Hodgkin lymphoma , 2016, Medicine.
[27] J. Kochenderfer,et al. Chimeric antigen receptor T-cell therapies for lymphoma , 2018, Nature Reviews Clinical Oncology.
[28] R. Gascoyne,et al. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. , 2015, Blood.
[29] E. Jaffe,et al. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. , 2009, Hematology. American Society of Hematology. Education Program.
[30] G. Salles. Clinical features, prognosis and treatment of follicular lymphoma. , 2007, Hematology. American Society of Hematology. Education Program.